Dr. Reddy’s Laboratories said that it has acquired several mometasone and mometasone/azelastine nasal sprays for the treatment of seasonal and perennial allergic rhinitis from Glenmark for Russia, Kazakhstan, Uzbekistan, and Ukraine. The brands included in the deal include Momat Rino (Russia, Kazakhstan, Uzbekistan); Momat Rino Advance (Russia), Momat A (Kazakhstan, Uzbekistan); Glenspray (Ukraine); and Glenspray Active (Ukraine).
Dr. Reddy’s CEO, Branded Markets, M V Ramana commented, “The new brands are a great addition to our product portfolio in Russia, Ukraine, Kazakhstan, and Uzbekistan which are important core markets for us. Momat Rino, the largest brand acquired, has recently received OTC registration in Russia and this will enable accelerated access of this product to patients. The acquired products will further add to Dr. Reddy’s strong presence in the anti-allergy segment in these countries, and will also enable us to offer a more comprehensive solution to patients in this area.”
Glenmark Pharmaceuticals Limited Chief Commercial Officer Robert Crockart said,”In line with our strategy to launch Ryaltris, our global anti-allergy brand, in the markets of Russia and other CIS countries, we decided to divest the Momat Rino brand and its extension. As we await approval to launch Ryaltris in the Russian market, we look forward to strengthening our respiratory franchise in the Russia/CIS region. We remain committed to the respiratory space globally.”
Read the Dr. Reddy’s press release.
Read the Glenmark Pharmaceuticals press release.
